<oai_dc:dc xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:date>2026</dc:date>
  <dc:type xml:lang="ita">Documento PDF</dc:type>
  <dc:type xml:lang="ita">Articolo scientifico</dc:type>
  <dc:description xml:lang="eng">Background/Objectives: Radiolabeled fibroblast activation protein inhibitors (FAPIs) are emerging as promising imaging agents assessing fibrotic diseases. This study evaluates [68Ga]Ga-DATA5m.SA.FAPi for imaging pulmonary fibrosis in two mouse models, bleomycin-induced (BLM) and a transgenic (fra-2tg) model, both displaying characteristics of human pulmonary fibrotic diseases. Methods: In the BLM model, C57BL/6 mice were treated with bleomycin or isotonic sodium chloride (controls) for 4, 5, and 6 weeks, followed by [68Ga]Ga-DATA5m.SA.FAPi PET/CT scans. Fra-2tg mice and wildtype (WT) littermates underwent at 7, 11, and 18/19 weeks of age a PET/CT scan. The selected timepoints correspond to early, middle, and late disease stages for each model. Imaging was complemented by ex vivo quantification, histological, and immunohistochemical (IHC) analyses. Results: In BLM mice, pulmonary [68Ga]Ga-DATA5m.SA.FAPi uptake showed a trend toward increase as early as 5 weeks of treatment compared with the controls, which was confirmed by ex vivo analysis (BLM: 3.31 ± 0.29%ID/g, n = 5; control: 1.61 ± 0.29%ID/g, n = 4; p = 0.0035). In fra-2tg mice, no significant differences could be detected. IHC revealed elevated pulmonary FAP expression specifically at early (BLM) and mild (fra-2tg) disease stages, whereas for BLM, tracer uptake was more pronounced at later stages. Conclusions: Our findings complement and extend observations from previous studies and support the potential of FAPI tracers as molecular imaging agents for pulmonary fibrosis.</dc:description>
  <dc:rights>http://creativecommons.org/licenses/by/4.0/</dc:rights>
  <dc:type xml:lang="deu">Text</dc:type>
  <dc:type xml:lang="deu">Wissenschaftlicher Artikel</dc:type>
  <dc:identifier>doi:10.3390/ph19010034</dc:identifier>
  <dc:title xml:lang="eng">FAPI Tracer en Vogue: Evaluating [68Ga]Ga-DATA5m.SA.FAPi for Molecular Imaging of Pulmonary Fibrosis</dc:title>
  <dc:creator>Victoria Weissenböck</dc:creator>
  <dc:creator>Michaela Schlederer</dc:creator>
  <dc:creator>Latifa Bakiri</dc:creator>
  <dc:creator>Johanna Schaffenrath</dc:creator>
  <dc:creator>Erwin F. Wagner</dc:creator>
  <dc:creator>Frank Rösch</dc:creator>
  <dc:creator>Marcus Hacker</dc:creator>
  <dc:creator>Lukas Kenner</dc:creator>
  <dc:creator>Cécile Philippe</dc:creator>
  <dc:subject xml:lang="eng">FAP</dc:subject>
  <dc:subject xml:lang="eng">Fibrosis</dc:subject>
  <dc:subject xml:lang="eng">PET</dc:subject>
  <dc:subject xml:lang="eng">Bleomycin</dc:subject>
  <dc:subject xml:lang="eng">Fra-2</dc:subject>
  <dc:format>application/pdf</dc:format>
  <dc:source xml:lang="eng">Pharmaceuticals</dc:source>
  <dc:language>eng</dc:language>
  <dc:rights xml:lang="ita">Open Access</dc:rights>
  <dc:type xml:lang="eng">Text</dc:type>
  <dc:type xml:lang="eng">journal article</dc:type>
  <dc:rights xml:lang="eng">© 2025 by the authors</dc:rights>
  <dc:rights xml:lang="eng">open access</dc:rights>
  <dc:publisher>MDPI</dc:publisher>
  <dc:identifier>https://phaidra.vetmeduni.ac.at/o:5361</dc:identifier>
</oai_dc:dc>